DSRL.F Stock Overview
Engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
DiaSorin S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €107.88 |
| 52 Week High | €109.00 |
| 52 Week Low | €88.45 |
| Beta | 0.19 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | 11.03% |
| 33 Year Change | -51.18% |
| 5 Year Change | n/a |
| Change since IPO | 476.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| DSRL.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | 1.5% | 2.2% |
| 1Y | 11.0% | 20.8% | 31.6% |
Return vs Industry: DSRL.F underperformed the US Medical Equipment industry which returned 20.8% over the past year.
Return vs Market: DSRL.F underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| DSRL.F volatility | |
|---|---|
| DSRL.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DSRL.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine DSRL.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 3,186 | Carlo Rosa | diasoringroup.com/en |
DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIASON IQ, LIAISON XL, LIAISON XXL, and LIAISON XL LAS. It also offers molecular diagnostics platforms comprising of LIAISON NES, a new molecular platform to address the growing diagnostic decentralization trend; the ARIES and ARIES M1 systems; LIAISON MDX, a thermocycler with two consumable disc options; LIAISON MDX Plus; MAGPIX System; Luminex 100/200 System; VERIGENE System; and the LIAISON PLEX System.
DiaSorin S.p.A. Fundamentals Summary
| DSRL.F fundamental statistics | |
|---|---|
| Market cap | US$6.01b |
| Earnings (TTM) | US$198.20m |
| Revenue (TTM) | US$1.24b |
30.3x
P/E Ratio4.9x
P/S RatioIs DSRL.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DSRL.F income statement (TTM) | |
|---|---|
| Revenue | €1.18b |
| Cost of Revenue | €406.02m |
| Gross Profit | €772.19m |
| Other Expenses | €583.34m |
| Earnings | €188.85m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.54 |
| Gross Margin | 65.54% |
| Net Profit Margin | 16.03% |
| Debt/Equity Ratio | 42.6% |
How did DSRL.F perform over the long term?
See historical performance and comparison